-
Exports of medical devices grew sharply High-end medical device exports were weak
Time of Update: 2021-03-04
exports of medical devices grew at a On November 19, the official website of the State Council forwarded an article in the People's Daily, which pointed out that in the first 10 months, China's total value of foreign trade imports and exports reached 25.63 trillion yuan, an increase of 2.4% year-on-year, of which exports amounted to 13.99 trillion yuan, an increase of 4.9%.
-
Bo Ruikang a round of financing 60 million yuan to accelerate the "brain-machine interface" technology landing clinical
Time of Update: 2021-03-04
Huang Xiaoshan, general manager of Bo Ruikang, said that this round of financing funds is mainly used to accelerate the development of clinical products, to promote minimally invasion implanted feedback therapy and brain-computer intelligent active rehabilitation of products landing.
-
Aiji Taikang completed 50 million yuan B round of financing, Jinke Jun venture capital lead investment
Time of Update: 2021-03-04
Focusing on research and development innovations in high-volume sequencing target capture technology and the design and production of gene testing products, Aji taikang is a production service platform company driven by gene testing technology.
-
Baiji Shenzhou's latest response: The allegations in the short report are blatantly false
Time of Update: 2021-03-04
Capital Research, a capital research firm, released a report saying that Baiji state may have "faked" sales.
Notably, Baiji Shenzhou has not responded to seven questions in the short report of J.Capital Research, a capital research firm.
-
Tianying Pharmaceuticals intends to set up a medical clinic management department
Time of Update: 2021-03-04
10 years of nine losses of the Tianmen pharmaceutical industry, this layout of rural medical care, whether to panic, or to renew the face, make a comeback?
-
Haizheng Pharmaceuticals gave a controlling stake in its subsidiary of $3.828 billion or eased its $10 billion debt
Time of Update: 2021-03-04
Recently, Haizheng Pharmaceuticals announced that the Taiwan Stock Exchange confirmed the delisting of Taizheng Investment Group (one of Asia's largest independent alternative investment management g
-
Step Pharmaceuticals set up a number of subsidiaries will transform scientific research
Time of Update: 2021-03-04
public opinion dispersed, step-by-step pharmaceutical voice, will transform scientific research, get rid of the marketing-oriented pharmaceutical company image. ▍ from marketing to scientific resea
-
Innovative medicine blows! Hengrui's half-year revenue of 10 billion Chinese biopharmaceuticals 12.5 billion
Time of Update: 2021-03-04
In fact, as the largest pharmaceutical company by market capitalization in China, Hengrui Pharmaceuticals has also begun to shift its research and development focus to innovative pharmaceuticals, according to the semi-annual report, in the first half of 2019 Hengrui Pharmaceuticals invested 1,484 million yuan in research and development, an increase of 49.13 percent over the same period last year, and the proportion of research and development investment in sales revenue reached 14.80 percent.
-
Yinchuan City prescriptions all outflow, to solve the problem of licensing practicing pharmacists
Time of Update: 2021-03-04
Yinchuan City prescription audit and transfer platform access to 6 municipal hospitals, hospital prescriptions all outflow, in addition, Yinchuan City Health and Health Commission Director Ma Xiaofei made it clear that the platform solved the problem of licensing practicing pharmacists.
-
Ji Pharmaceutical Holdings intends to acquire a 100% stake in Amended Pharmaceuticals, Jilin's richest man or shell listing
Time of Update: 2021-03-04
Correction pharmaceutical industry or shell listing corrective pharmaceutical industry official website shows that the company's chairman Xiu Yugui founded, is concentrated in pharmaceutical, chemical pharmaceutical, biopharmaceutical research and production marketing, drug chain management, Traditional Chinese medicine standard cultivation in one of the large-scale modern private pharmaceutical enterprises.
-
Dongguan public hospitals to propose or reduce the price of medicines and medical supplies
Time of Update: 2021-03-04
"Reform Plan" revealed that the "Dongguan City public medical institutions basic medical services prices" "except content" and "description" has clearly defined the additional charges of one-time consumption materials, in 2016 to cancel the actual purchase price of more than 300 yuan on the basis of the supplies, a full increase in consumption materials.
-
Circulation enterprises change bureau 510,000 armed enterprises face a large number of elimination!
Time of Update: 2021-03-04
"China's national medicine, medicine, China Resources, Kyushua to the four major circulation enterprises, accounting for less than 40% of the national circulation share, the concentration of the equipment industry is worse, but in Europe and the United States, Japan, the industry head circulation enterprises in the market share of more than 75%, or even as high as 95%." The above-mentioned person in charge said.
-
The shortage of cheap drugs has eased this year
Time of Update: 2021-03-04
Recently, the supply of glyceal nitrate also caused the concern of Premier Li Keqiang of the State Council, admonished "to do a good job of commonly used drugs, first aid drugs to ensure stable prices, must not be out of stock, must not be wayetic price increases." The National Health and Safety Commission and other departments jointly issued a series of policies to address the shortage of drugs, targeted to solve the problem of drug supply.
-
Kingsley and Seymru will work together in the life sciences and pharmaceuticals
Time of Update: 2021-03-04
August 19th, Kingsley Biotech (hereinafter: Kingsley) and Somerset Technologies (hereinafter referred to as Seymru) announced that they will jointly launch a comprehensive cooperation in the field of life sciences and biopharmaceuticals to jointly promote the development of the entire industrial chain of biopharmaceuticals from research and development to production.
-
The second batch of volume purchase lists flowed out of generic drugs to kill prices or more violently
Time of Update: 2021-03-04
From the industry spread "on the reporting and expansion of national organizations centralized procurement and use of drug varieties related procurement data notice", the current round of volume procurement involving a total of 35 drugs, a caposaccharide, metformin, albumin yew alcohol, tadalafa and other popular large varieties in the column.
-
Pre-loss of more than 2.2 billion yuan! People's fu medicine 3 billion goodwill "thunderstorm" landed at once
Time of Update: 2021-03-04
fu medicine has recently attracted market attention. First at the end of 2018 Fentanne "black swan" event, and then in January this year, the company's earnings forecast showed a sharp decline, the s
-
6 provinces and regions set up a new free trade test zone, the development of the pharmaceutical industry focus!
Time of Update: 2021-03-04
On August 26, the State Council issued approval for the establishment of six new free trade pilot zones, agreeing to establish the China (Shandong) Free Trade Pilot Zone, the China (Jiangsu) Free Tr
-
Pharmaceutical companies each make big moves to be shortlisted for the health insurance catalog
Time of Update: 2021-03-04
National opportunities brought about by the adjustment of the medical insurance catalogue As the largest payer of China's pharmaceutical market, the importance of drug release is self-evident, especially for the more expensive innovative drugs, included in the medical insurance catalog, on the one hand, can reduce the burden of patients, on the other hand, also increase the willingness of hospitals to use drugs.
-
Increased concentration in the industry Well-known pharmaceutical companies are being sold
Time of Update: 2021-03-04
China Resources Pharmaceuticals acquisition jiangzhong On April 17, Jiangzhong Pharmaceutical Co., Ltd. announced that it had recently received a notice from the company's controlling shareholder, approved by the Jiangxi Provincial Market Supervision Administration, and that the controlling shareholder had completed the registration of industrial and commercial changes in the name and scope of business of the enterprise on April 8, 2019.
-
Takeda Pharmaceuticals, the pharmaceutical industry's "snake swallowing elephant," will buy Shire for $58 billion
Time of Update: 2021-03-04
On December 5, local time, Takeda, the Japanese pharmaceutical group, announced the results of a shareholder meeting in which Takeda's shareholders approved the acquisition of Shire, the British maker of rare diseases.
